Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-24

Study Completion Date

2022-03-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

is an open label, randomized, multicenter phase II trial

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

NCT03603834

Cholangiocarcinoma

UNKNOWN PHASE2

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

NCT03279289

Metastatic Colorectal Cancer

COMPLETED PHASE2

mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line

NCT03464968

Biliary Cancer Metastatic

COMPLETED PHASE2

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

NCT00021281

Colorectal Cancer

UNKNOWN PHASE3

Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer

NCT00005979

Colorectal Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to assess the efficacy of nal-IRI in gemcitabine pre-treated patients with advanced, unresectable and metastatic cholangio- and gallbladder carcinoma eligible for treatments after failure to respond to a gemcitabine-based treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholangiocarcinoma Non-resectable Cholangiocarcinoma Metastatic Cholangiocarcinoma of the Gallbladder Cholangiocarcinoma Advanced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nal-IRI + 5-FU + leucovorin (Arm A)

nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion), 5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)

Group Type EXPERIMENTAL

nal-IRI

Intervention Type DRUG

nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)

5-FU

Intervention Type DRUG

5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)

leucovorin

Intervention Type DRUG

leucovorin (400 mg/m2 as 0.5 hour infusion)

5-FU + leucovorin (Arm B)

Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)

Group Type OTHER

5-FU

Intervention Type DRUG

5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)

leucovorin

Intervention Type DRUG

leucovorin (400 mg/m2 as 0.5 hour infusion)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nal-IRI

nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)

Intervention Type DRUG

5-FU

5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)

Intervention Type DRUG

leucovorin

leucovorin (400 mg/m2 as 0.5 hour infusion)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
2. Age ≥ 18 years at time of study entry
3. Histologically or cytologically confirmed, non-resectable, locally advanced or metastatic cholangiocarcinoma or gall bladder carcinoma
4. Measurable or assessable disease according to RECIST 1.1
5. Documented disease progression after prior gemcitabine or gemcitabine containing therapy, in locally advanced or metastatic setting. Examples of permitted therapies include, but are not limited to:

1. Single agent gemcitabine
2. Any one gemcitabine-based regimen, with or without maintenance gemcitabine
6. ECOG performance status 0-1
7. Adequate blood count, liver-enzymes, and renal function:

* ANC \> 1,500 cells/μL without the use of hematopoietic growth factors; and
* Platelet count ≥ 100 x 10\^9/L (\>100,000 per mm³) and
* Hemoglobin \> 9 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 9 g/dL)
* Serum total bilirubin ≤ 3x upper normal limit (ULN) (biliary drainage is allowed for biliary obstruction; elevated bilirubin should be caused by obstruction not impaired liver function as assessed by albumin and INR values):
* Albumin levels ≥ 3.0 g/dL
* Patients not receiving therapeutic anticoagulation must have an INR \< 1.5 ULN and PTT \< 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization
* AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal
* Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute
8. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of treatment.
9. Subject is willing and able to comply with the protocol (including contraceptive measures) for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria

1. Active CNS metastases (indicated by clinical symptoms, cerebral oedema, steroid requirement, or progressive disease); patient should have been off steroids for at least 28 days prior to starting study therapy
2. Clinically significant gastrointestinal disorder including bleeding, inflammation, occlusion, or diarrhoea \> grade 1
3. History of any second malignancy in the last 5 years; subjects with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years.
4. Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes or an unexplained fever \> 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, patients with tumour fever may be enrolled), which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome.
5. Premalignant hematologic disorders, e.g. myelodysplastic syndrome
6. Pre-existing lung disease
7. Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment
8. History of hypersensitivity to any of the study drugs or any excipient (nal-IRI, other liposomal products, fluoropyrimidines or leucovorin)
9. Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
10. Severe non-healing wounds, ulcers or bone fractions
11. Evidence of bleeding diathesis or coagulopathy
12. Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.
13. Medication that is known to interfere with any of the agents applied in the trial.
14. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). \[Acceptable methods of contraception are:implants, injectable contraceptives, combined oral contraceptives, intrauterine pessaries (only hormonal devices), sexual abstinence or vasectomy of the partner\].
15. Known Gilbert-Meulengracht syndrome
16. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
17. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 5 half-lifes of previously used trial medication, whichever is of longer duration.
18. Previous enrollment or randomization in the present study (does not include screening failure).
19. Previous enrollment in the NIFE trial \[AIO-YMO/HEP-0315\]
20. Involvement in the planning and/or conduct of the study (applies to both Baxalta staff and/or staff of sponsor and study site)
21. Patient who might be dependent on the sponsor, site or the investigator
22. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
23. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \[§ 40 Abs. 1 S. 3 Nr. 3a AMG\].

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No